Center for Oral Infectious Diseases
Scott Kachlany, Ph.D.
Dr. Scott Kachlany is currently an Associate Professor in the Department of Oral Biology. He received his B.S. from Cornell University in Microbiology and Molecular and Cellular Biology in 1997. He received his Ph.D. in Microbiology from Columbia University College of Physicians and Surgeons in 2001. He continued at Columbia as a Postdoctoral Research Fellow until 2003.
Studies in my laboratory focus on the human pathogen Actinobacillus actinomycetemcomitans. A. actinomycetemcomitans is the etiologic agent of localized aggressive periodontitis (LAP), a very rapid and destructive disease of the oral cavity affecting predominantly adolescents. A. actinomycetemcomitans is also part of the HACEK (Haemophilus aphrophilus, A. actinomycetemcomitans, Cardiobacterium hominis, Eikenella corrodens, Kingella kingae) group of bacteria that cause infective endocarditis. We are specifically interested in an important toxin produced by the pathogen, leukotoxin. Leukotoxin is part of the RTX (repeat in toxin) family of toxins, typified by E. coli a-hemolysin and Bordetella pertussis adenylate cyclase. In contrast to the less specific a-hemolysin, leukotoxin specifically destroys human and Old World primate leukocytes. Leukotoxin likely plays a significant role in pathogenesis by helping A. actinomycetemcomitans evade host immune defenses. Our overall goals are to better understand how leukotoxin functions as a virulence factor and how it contributes to disease caused by A. actinomycetemcomitans. Ultimately, we hope that our work will lead to the identification of novel ways to prevent toxin function and combat disease.
Kachlany, S. C., Schwartz, A. B., Balashova, N. V.,
Hioe, C. E.,Tuen, M., Le, A., Kaur, M., Mei, Y., and J. Rao.
2010. Anti-leukemia activity of a bacterial toxin with natural
specificity for LFA-1 on
white blood cells. Leukemia Research. 34: 777-785. PMID: 19747730
Kachlany, S. C. 2010. Aggregatibacter actinomycetemcomitans leukotoxin: from threat to therapy. Journal of Dental Research. 89:561-570. PMID: 20200418
Forman, M. S., Nishikubo, J. B., Han, R. K., Le, A., Balashova, N.V.,
Kachlany, S. C. 2010. Gangliosides
Block Aggregatibacter actinomycetemcomitans Leukotoxin (LtxA)-Mediated Hemolysis." Toxins 2, no. 12: 2824-2836.
Maldonado R., Wei R., Kachlany S. C., Kazi M., Balashova N. V.2011. Cytotoxic effects of Kingella kingae outer membrane vesicles on human cells. Microbial Pathogenesis. 51:22-30. PubMed PMID: 21443941.
Stenderup, K., Rosada, C., Dam, T. N., Salerno, E., Belinka, B. A., and
Kachlany, S. C. 2011. Resolution
of psoriasis by a leukocyte-targeting bacterial protein in a humanized mouse model. Journal of Investigative Dermatology. 131: 2033-2039.
Bendaoud, M., Vinogradov, E., Balashova, N. V., Kadouri, D. E.,
Kachlany, S. C., Kaplan, J. B. 2011. Broad spectrum biofilm inhibition by Kingella kingae
exopolysaccharide. Journal of Bacteriology. 193: 3879-86.
Gupta, A., Le, A., Belinka, B. A., Kachlany, S. C. 2011. In vitro synergism between LFA-1 targeting leukotoxin (LeukotheraTM) and standard chemotherapeutic agents in leukemia cells. Leukemia Research. 35:1498-1505.
Hioe, C. E., Tuen, M., Vasiliver-Shamis, G, Alvarez, Y., Prins, K.C., Banerjee, S., Cho, M. W., Dustin, M.L., and Kachlany, S. C. 2011. HIV envelope gp120 activates LFA-1 on CD4 T-lymphocytes and increases cell susceptibility to LFA-1-targeting leukotoxin (LtxA). PLoS ONE. 6: e23202.
Monday, June 5, 2006